|
|
|
|
LEADER |
00000nam a22000005i 4500 |
001 |
978-1-4614-5851-7 |
003 |
DE-He213 |
005 |
20220119080305.0 |
007 |
cr nn 008mamaa |
008 |
130131s2013 xxu| s |||| 0|eng d |
020 |
|
|
|a 9781461458517
|9 978-1-4614-5851-7
|
024 |
7 |
|
|a 10.1007/978-1-4614-5851-7
|2 doi
|
050 |
|
4 |
|a RC261-271
|
072 |
|
7 |
|a MJCL
|2 bicssc
|
072 |
|
7 |
|a MED062000
|2 bisacsh
|
072 |
|
7 |
|a MJCL
|2 thema
|
082 |
0 |
4 |
|a 571.978
|2 23
|
082 |
0 |
4 |
|a 616.994
|2 23
|
245 |
1 |
0 |
|a Non-Hodgkin Lymphoma
|h [electronic resource] :
|b Prognostic Factors and Targets /
|c edited by Peter J. Quesenberry, Jorge J. Castillo.
|
250 |
|
|
|a 1st ed. 2013.
|
264 |
|
1 |
|a New York, NY :
|b Springer New York :
|b Imprint: Humana,
|c 2013.
|
300 |
|
|
|a VI, 304 p.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
490 |
1 |
|
|a Cancer Drug Discovery and Development,
|x 2196-9914
|
505 |
0 |
|
|a Cancer Stem Cells: A Matter of Perspective -- B and T-cell development -- HIV lymphomagenesis -- Epstein-Barr Virus Lymphomagenesis and Therapeutic Targets -- Antigen driven lymphomagenesis -- Pre-clinical lymphoma models -- Prognostic factors in B-cell lymphoma -- Prognostic factors in T-cell lymphoma -- Prognostic factors in HIV-associated lymphoma -- Future directions on the treatment of aggressive non-Hodgkin lymphoma -- New monoclonal antibodies for indolent non-Hodgkin lymphomas -- Current therapies for T-cell lymphoma -- Stem Cell Transplantation for lymphoma -- Autologous stem cell transplantation in non-Hodgkin lymphoma -- The role of Stem Cell Transplantation for HIV-associated lymphoma -- Stem Cell Transplantation for T-cell lymphoma -- Index.
|
520 |
|
|
|a Recent developments in the therapy of non-Hodgkin lymphoma have improved response and survival rates in patients with these conditions. This book is focused on the biology, prognostic factors and novel targets of non-Hodgkin lymphoma. We believe that understanding the pathophysiology of non-Hodgkin lymphoma provides a mean to improve its risk-stratification and treatment. This book is intended for medical and healthcare professionals involved in the research and clinical care of patients with non-Hodgkin lymphoma.
|
650 |
|
0 |
|a Cancer.
|
650 |
|
0 |
|a Pharmacology.
|
650 |
1 |
4 |
|a Cancer Biology.
|
650 |
2 |
4 |
|a Pharmacology.
|
700 |
1 |
|
|a Quesenberry, Peter J.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
700 |
1 |
|
|a Castillo, Jorge J.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer Nature eBook
|
776 |
0 |
8 |
|i Printed edition:
|z 9781461458524
|
776 |
0 |
8 |
|i Printed edition:
|z 9781489994196
|
776 |
0 |
8 |
|i Printed edition:
|z 9781461458500
|
830 |
|
0 |
|a Cancer Drug Discovery and Development,
|x 2196-9914
|
856 |
4 |
0 |
|u https://doi.uam.elogim.com/10.1007/978-1-4614-5851-7
|z Texto Completo
|
912 |
|
|
|a ZDB-2-SME
|
912 |
|
|
|a ZDB-2-SXM
|
950 |
|
|
|a Medicine (SpringerNature-11650)
|
950 |
|
|
|a Medicine (R0) (SpringerNature-43714)
|